While the collaboration was announced on 20 July 2023 RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
I should remind existing & prospective holders when the below was released: June 2024
LOS ALTOS, CA – June 10, 2024 – RenovoRx, Inc. – (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships.
Now! of all the things Ryan could have said he chose to say: “RenovoRx is at an important juncture, and I am excited to step into this role on a permanent basis. Building off our collaboration with Imugene and clinical data delivering gemcitabine with our drug-delivery platform, there is incredible potential for RenovoRx’s technology. "
This statement by Ryan is the reason I'm welded on here; it's not about the equity curve on this one, I either go home rich, or I go home broke. imo
IMU Price at posting:
3.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)